कंपनी का अवलोकन
Semler Scientific, Inc. operates as a provider of specialized technology solutions designed to enhance the clinical effectiveness and operational efficiency of healthcare providers within the United States. The company focuses on medical devices, specifically offering products like QuantaFlo, which functions as a four-minute in-office blood flow test enabling precise blood flow measurements for clinical use. This entity functions within the broader Healthcare sector, specifically categorized under the Medical Devices industry, indicating its role in supporting diagnostic and therapeutic procedures. As of the latest data, the company holds a market capitalization of $311.11 million and generates annual revenue of $36.96 million while employing a workforce of 79 individuals. These financial figures suggest that Semler Scientific is a small-cap entity with a relatively modest revenue base, positioning it as a niche player rather than a dominant market leader in the medical device landscape.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $36.96 million alongside a net income of $48.34 million and an EBITDA of -$5,020,000. The notable discrepancy where net income exceeds revenue while EBITDA remains negative reveals a highly unusual cost structure, likely driven by significant non-cash expenses or accounting adjustments that inflate reported profit while obscuring underlying operational cash burn. Free cash flow stands at -$33,146,500, indicating that the company is currently consuming cash reserves to fund operations or capital expenditures, which limits its immediate financial flexibility and ability to finance growth without external capital. The gross margin is exceptionally high at 90.8%, suggesting strong pricing power or low cost of goods sold, yet the operating margin is deeply negative at -72.0%, pointing to substantial overhead costs that are not covered by operating income. Despite these operational losses, the profit margin registers at 130.8%, a metric that appears anomalous given the negative EBITDA and requires careful scrutiny of non-operating income or one-time gains. On the balance sheet, total cash holdings of $10.18 million are significantly outweighed by total debt of $116.42 million, resulting in a debt-to-equity ratio of 25.32, which signifies a highly leveraged financial position rather than a conservative one. The current ratio of 1.97 indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting adequate short-term liquidity despite the heavy debt load. Return on equity is reported at 17.7%, while return on assets is -1.0%, a divergence that highlights how leverage and specific accounting treatments impact the perceived effectiveness of management in generating returns on shareholder capital versus the total asset base.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 3.93, while the forward P/E ratio is 254.43, a stark divergence that implies market expectations of a massive increase in future earnings or a temporary anomaly in current earnings that distorts the valuation multiple. The price-to-book ratio stands at 0.67, indicating that the market values the company at a discount relative to its book value, which often suggests a market perception of underlying asset risks or a lack of growth prospects in the current business model. The price-to-sales ratio is 8.42, and the EV/EBITDA is -82.56, suggesting that traditional valuation metrics based on earnings are less reliable here due to the negative EBITDA, while the high P/S multiple reflects investor willingness to pay a premium for potential future recovery or specific asset value. The stock's 52-week high is $54.40 and the 52-week low is $14.88, placing the current trading price within a range that reflects significant volatility over the past year. The beta value of 1.32 indicates that the stock's price volatility is 32% higher than the broader market, suggesting it is more sensitive to market fluctuations and may experience sharper swings during periods of market uncertainty.
Growth & Income
Revenue growth year-over-year stands at -44.6%, while earnings growth year-over-year is 49.3%, revealing a scenario where earnings are growing significantly faster than revenue, a phenomenon often associated with cost-cutting measures or non-recurring income rather than organic top-line expansion. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all earnings rather than distributing them to shareholders. Consequently, the company reinvests its earnings, or in this case, its capital structure adjustments, back into the business to support operations, research, or debt management rather than providing income to investors. The overall growth and income profile is characterized by a contraction in sales revenue paired with volatile earnings growth and a complete absence of dividend income, presenting a high-risk, high-volatility investment characteristic typical of distressed or turnaround situations in the medical device sector.